1 Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. W Bannister, A Cozzi-Lepri, J Kjær, B Clotet, A Lazzarin, JP Viard, G Kronborg, D Duiculescu, M Beniowski, L Machala, A Phillips;
J Antimicrob Chemother.2011 Apr;66(4):901-11. Epub 2011 Jan 31. abstract

2 Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, JD Lundgren, M Law; for the D:A:D study group.
HIV Med. 2011 Aug;12(7):412-21. doi: 10.1111/j.1468-1293.2010.00901.x. Epub 2011 Jan 20. abstract

3 Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. A Arenas-Pinto, A Grant, K Bhaskaran, A Copas, A Carr, SW Worm, E Martinez, P Reiss, D Dunn, R Weber, J Hoy, I Weller, the Lactic Acidosis International study group.
Antivir Ther. 2011;16(2):219-26. abstract

4 Factors associated with the development of cytomegalovirus infection following solid organ transplantation. C da Cunha-Bang, SS Sørensen, M Iversen, VH Sengel, JG Hillings, A Rasmussen, SA Mortensen, ZV Fox, NS Kirkby, CB Christiansen, JD Lundgren.
Scand J Infect Dis. 2011 May;43(5):360-5. Epub 2011 Feb 9]. abstract

5 Regarding: humar et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. C da Cunha-Bang, M Iversen, SA Mortensen, A Rasmussen, H Sengeløv, SS Sørensen, J Lundgren.
Am J Transplant. 2011 Feb;11(2):408. doi: 10.1111/j.1600-6143.2010.03349.x. Epub 2011 Jan 10. abstract

6 A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. JD Kowalska, A Mocroft, B Ledergerber, E Florence, M Ristola, J Begovac, H Sambatakou, C Pedersen, JD Lundgren, O Kirk, for the EuroSIDA study group.
HIV Clin Trials. 2011 Mar-Apr;12(2):109-17. abstract

7 Acute hepatitis C in HIV-infected individuals- recommendations from the NEAT consensus conference. JK Rockstroh; The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel.
AIDS. 2011 Feb 20;25(4):399-409. abstract

8 Risk of triple-class virological failure in children with HIV: a retrospective cohort study.Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), H Castro, A Judd, DM Gibb, K Butler, RK Lodwick, A van Sighem, JT Ramos, J Warsawski, C Thorne, A Noguera-Julian, N Obel, D Costagliola, PA Tookey, C Colin, J Kjaer, J Grarup, G Chene, A Phillips.
Lancet. 2011 May 7;377(9777):1580-7. Epub 2011 Apr 20. abstract

9 HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. Working Group on Estimation of HIV Prevalence in Europe.
AIDS. 2011 May 15;25(8):1017-23. abstract

10 Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro, AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25. abstract

11 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practise across Europe : A EuroSIDA study.J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fatkenhaeur, JD Lundgren, A Mocroft.
HIV Med. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31.abstract

12 The Coding Causes of Death in HIV (CoDe) Project- Initial Results and Evaluation of Methodology. JD Kowalska, N Friis-Møller, O Kirk, W Bannister, A Mocroft, C Sabin, P Reiss, J Gill, C Lewden, A Phillips, A d'Arminio Monforte, M Law, J Sterne, S De Wit, JD Lundgren, the CoDe working group and the D:A:D study group.
Epidemiology. 2011 Jul;22(4):516-523. [Epub ahead of print]. abstract

13 Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. A Kruk, W Bannister, D Podlekareva, N Chentsova, A Rakhmanova, A Horban, P Domingo, A Mocroft, J Lundgren, O Kirk; on behalf of the EuroSIDA study group.
AIDS. 2011 JUl 31;25(12):1505-13. Epub ahead of print 2011 May 21 . abstract

14 Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. JP Viard, JC Souberbielle, O Kirk, J Reekie, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, JD Lundgren, A Mocroft for the EuroSIDA Study Group.
AIDS. 2011 Jun 19;25(10):1305-1315. abstract

15 The metabolic syndrome in HIV. SW Worm, JD Lundgren.
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):479-86. doi: 10.1016/j.beem.2010.10.018. abstract

16 Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study. SW Worm, DA Kamara, P Reiss, O Kirk, W El-Sadr, C Fux, E Fontas, A Phillips, AD Monforte, S De Wit, K Petoumenos, N Friis-Møller, P Mercie, J Lundgren, C Sabin.
AIDS. 2011 Jul 31;25(12):1497-504. abstract

17 Antibiotics in intensive care: too little or too much? ME Johansen, JU Jensen, JD Lundgren.
Crit Care Med. 2011 Jul;39(7):1849-51. abstract

18 Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobialtherapy. M Suppli, R Aabenhus, ZB Harboe, LP Andersen, M Tvede, JU Jensen. Clin Microbiol Infect. 2011 Jul;17(7):1078-83. doi:10.1111/j.1469-0691.2010.03394.x. Epub 2010 Dec 3. abstract

19 The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, AD Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin.
J Infect Dis. 2011 Aug;204(4):521-525. abstract

20 Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. JU Jensen, L Hein, B Lundgren, MH Bestle, TT Mohr, MH Andersen, KJ Thornberg, J Løken, M Steensen, Z Fox, H Tousi, P Søe-Jensen, AØ Lauritsen, D Strange, PL Petersen, N Reiter, S Hestad, K Thormar, P Fjeldborg, KM Larsen, NE Drenck, C Ostergaard, J Kjær, J Grarup, JD Lundgren; Procalcitonin And Survival Study (PASS) Group.
Crit Care Med. 2011 Sep;39(9):2048-58. abstract

21 HIV infection, aging and cardiovascular disease: epidemiology and prevention. K Petoumenos, SW Worm.
Sex Health. 2011 Nov;8(4):465-73. abstract

22 Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. ZV Fox, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, AN Phillips, G Kronborg, J Kjaer, B Clotet, JD Lundgren for EuroSIDA.
Antivir. Ther. 2011;16(5):781-5. abstract

23 Hepatitis delta in HIV-infected individuals in Europe. V Soriano, D Grint, A d'Arminio Monforte, A Horban, C Leen, E Poveda, F Antunes, S de Wit, J Lundgren, J Rockstroh, L Peters.
AIDS. 2011 Oct 23;25(16):1987-92. abstract

24 Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. J Reekie, J Gatell, I Yust, E Bakowska, A Rakhmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft; EuroSIDA in EuroCoord.
AIDS. 2011 Nov 28;25(18):2259-68. abstract

25 Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam. DT Huong, W Bannister, PT Phong, O Kirk, L Peters.
Int J STD AIDS. 2011 Nov;22(11):659-64. abstract

26 Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. SMART Study Group, L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MD Klein.
Antivir Ther. 2011;16(5):667-75. abstract

27 Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? R Aabenhus, JU Jensen.
Prim Care Respir J. 2011 Dec;20(4):360-7. abstract.

28 A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. R Paredes, MC Puertas, W Bannister, M Kisic, A Cozzi-Lepri, C Pou, R Bellido, G Betancor, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, J Lundgren, L Menéndez-Arias, J Martinez-Picado; The EuroSIDA Study Group.
J Infect Dis. 2011 Sep 1;204(5):741-52. abstract

29 Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. EZ Soliman, JD Lundgren, MP Roediger, DA Duprez, Z Temesgen, M Bickel, JC Shlay, C Somboonwit, P Reiss, JH Stein, JD Neaton, INSIGHT SMART Study Group.
AIDS. 2011 Jan 28;25(3):367-77. abstract

30 Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. A Cozzi-Lepri, MCF Prosperi, J Kjær, D Dunn, R Paredes, CA Sabin, JD Lundgren, AN Phillips, D Pillay, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies.
PLoS One. 2011;6(11):e25665. Epub 2011 Nov 16. abstract

31 Cardiovascular implications from untreated human immunodeficiency virus infection. JV Baker, JD Lundgren.
Eur Heart J. 2011 Apr;32(8):945-51. Epub 2011 Jan 12. abstract

32 Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. JV Baker, J Neuhaus, D Duprez, LH Kuller, R Tracy, WH Belloso, S De Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, DE Nixon, NI Paton, JD Neaton, INSIGHT SMART Study Group.
J Acquir Immune Defic Syndr. 2011 Jan;56(1):36-43.abstract

33 Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AN Phillips, D Pillay, G Garnett, D Bennett, M Vitoria, V Cambiano, J Lundgren.
AIDS. 2011 Mar 27;25(6):843-50. abstract

34 Haemoglobin and anaemia in the SMART study. A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, MJ Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips, INSIGHT SMART Study Group.
Antivir Ther. 2011;16(3):329-37. abstract

35 Prevention of HIV-1 infection with antiretroviral therapy. A Rodger, A Phillips, J Lundgren.
N Engl J Med. 2011 Nov 17;365(20):1934; author reply 1935. abstract

36 Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. EZ Soliman, RJ Prineas, MP Roediger, DA Duprez, F Boccara, C Boesecke, C Stephan, S Hodder, JH Stein, JD Lundgren, JD Neaton.
J Electrocardiol. 2011 Nov-Dec;44(6):779-85. Epub 2010 Dec 8. abstract

37 The Global Fund’s resource allocation decisions for HIV programmes: addressing those in need. O Avdeeva, JV Lazarus, MA Aziz, R Atun.
J Int AIDS Soc. 2011 Oct 26;14:51. abstract

38 Critical Interactions between the Global Fund-Supported HIV Programs and the Health System in Ghana. R Atun, SK Pothapregada, J Kwansah, D Degbotse, JV Lazarus.
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S72-6. abstract

39 Attitude of Lithuanian Residents to Confidentiality of Adolescent Sexual and Reproductive health Care. L Jaruseviciene, JV Lazarus, A Zaborskis.
Central European J Public Health, 2011; 19(4): 211-217.

40 Overcoming obstacles to late presentation for HIV infection in Europe. JV Lazarus, R Jürgens, M Weait, A Phillips, J Hows, J Gatell, T Coenen, A Sönnerborg, D Raben and JD Lundgren.
HIV Med. 2011 Apr;12(4):264-9.

41 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice across Europe: a EuroSIDA study. J Reekie, P Reiss, B Ledergerber, D Sedlack, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft; for the EuroSIDA Study Group.
HIV Med. 2011 May;12(5):259-68.

42 Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), H Castro, A Judd, DM Gibb, K Butler, RL Lodwick, A van Sighem, JT Ramos, J Warsawski, C Thorne, A Noguera-Julian, N Obel, D Costagliola, PA Tookey, C Colin, J Kjær, J Grarup, G Chene, A Phillips.
Lancet. 2011 May 7;377(9777):1580-7.

Updated: 08 Apr 2013